Glenmark starts Phase-IIb human trials of Revamilast molecule
Glenmark Pharmaceuticals on Wednesday started Phase-IIb human trials of its 'Revamilast' molecule, which is being developed for treatment of inflammatory disorders like asthma and rheumatoid arthritis.
Glenmark Pharmaceuticals said on Monday it is planning to submit new drug application in the US for Crofelemer used in the treatment of HIV-associated diarrhoea.